Practical approaches on the long-acting injections
- 20 Downloads
Over the last several decades, long-acting injections have been studied in order to overcome such problems as low bioavailability in the oral route, the short durations of action in conventional injection, and the poor medication adherence in patients.
The authors classified long-acting injections into three categories, namely, molecular modification, nanovehicle carriers, and stimuli-responsive hydrogels. The mechanisms and practical cases of these long acting injectable formulations, including conventional and recent technologies, were described and discussed in this review.
Long-acting injection formulations has been proven to be useful from a number of preclinical and clinical studies. Therefore, the long-acting injection technologies can be promising strategy for precision and personalized medicine if the characteristics of formulation such as extended release and the drug-targeting are used appropriately.
KeywordsLong-acting injection Molecular modification Nanovehicle Hydrogel
This work was supported by the 2018 Inje University research grant.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involved in human and animal rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
- Bi YE, Zhou Y, Wang M, Li L, Lee RJ, Xie J, Teng L (2017) Targeted delivery of cordycepin to liver cancer cells using transferrin-conjugated liposomes. Anticancer Res 37:5207–5214Google Scholar
- Din FU, Kim DW, Choi JY, Thapa RK, Mustapha O, Kim DS, Oh YK, Ku SK, Youn YS, Oh KT, Yong CS, Kim JO, Choi HG (2017) Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration. Acta Biomater 54:239–248CrossRefGoogle Scholar
- Khan R, Irchhaiya R (2017) An overview on niosomes as efficient drug carriers. Int J Pharm Bio Sci 8:106–116Google Scholar
- Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M (2010) Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int. J Neuropharmacol 13(5):635–647Google Scholar
- Sun Y, Lu X, Gai Y, Sha C, Leng G, Yang X, Liu W (2018) LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies. J Chromatogr B 1081:67–75CrossRefGoogle Scholar
- Teekamp N, Van Dijk F, Broesder A, Evers M, Zuidema J, Steendam R, Post E, Hillebrands JL, Frijink HW, Poelstra K, Beljaars L, Olinga P, Hinrichs WLJ (2017) Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney. Int J Pharm 534:229–236CrossRefGoogle Scholar
- Verma P, Thakur AS, Deshmukh K, Jha AK, Verma S (2010) Routes of drug administration. Int J Pharm Stud Res 1:54–59Google Scholar
- Yao C, Liu J, Wu X, Tai Z, Gao Y, Zhu Q, Li J, Zhang L, Hu C, Gu F, Gao J, Gao S (2016) Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. J Control Release 232:203–214CrossRefGoogle Scholar